iiinova — where your digital self keeps evolving

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 30/05/2026

#asco26 #leusm Park: Obe-cel was detected in CSF of majority of patients. All in all best outcomes in those with <5% marrow blasts prior to LD+Obe-cel regardless of EMD status.

010

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 30/05/2026

#asco26 #leusm Park: those w EMD have similar DoR/EFS/OS as those wo EMD. Similar low CRS rates but more ICANS in those with EMD.

010

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 30/05/2026

#asco26 #leusm Park: Obe-cel outcomes in RR B-ALL with EMD. ORR 59% vs 83% in those w vs wo EMD. Incr to 71%/90% in those w <5% marrow blasts at time of LD.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 30/05/2026

#asco26 #leusm Goulart: dose dense mCVD/Ino/Blin for RR Ph neg B-ALL. 3yr EFS/OS 69%/79%. Consolidation w CART or alloHCT assoc with better outcomes.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 30/05/2026

#asco26 #leusm Goulart: dose dense mCVD/Ino/Blin for RR Ph neg B-ALL. 100% CR/CRp/i rate.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 30/05/2026

#asco26 #leusm Short: hCVAD/Blin w/wo Ino. 100% OS so far in those with Ino.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 30/05/2026

#asco26 #leusm Short: hCVAD/Blin w/wo Ino. These data continue to look great w caveat that there are more high risk pts in no Ino cohort.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 30/05/2026

#asco26 #leusm Nasr: with Blin+Ponat 4yr EFS/OS 79%/89% w only 2% allo on CR1.

100

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 30/05/2026

#asco26 #leusm Nasr: 4yr outcome data for Blin+Ponatinib in Ph+ ALL, including added IT chemo (15) + hCVAD B cycles x 2 in those w WBC >70.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 30/05/2026

#asco26 #leusm Jabbour: Olve generally well tolerated but only one pt beyond 1yr so far so will need to follow longer term data to determine cumulative AE risks.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 30/05/2026

#asco26 #leusm Jabbour: Olverembatinib + Blin for persistent MRD+ or TKI intolerant for Ph+ ALL and CML-BC, high response rates despite ~50% w prior exposure to Ponatinib and >60% w prior exposure to Blinatumomab.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 30/05/2026

#asco26 #leusm Pardee: selinexor added more N/V/D as expected but more went to allo with triple combo and maybe improved OS (not statsig).

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 30/05/2026

#asco26 #leusm Pardee: Selinexor with intensive chemo for ND-AML (excluding CBF and FLT3+). Halted early after Paradigm presented.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 30/05/2026

#asco26 #leusm Sengar: fewer new infections with reduced hospital contact and cost with A/V vs 7+3.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 30/05/2026

#asco26 #leusm Sengar: India study of 7+3 vs Aza/Ven21 (not randomized, single center) for ND-AML. Similar induction mortality despite higher age and more high risk dz with A/V.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 07/02/2026

#tandem26 Ferrara: JAKi facilitates tissue repair whereas steroids actually inhibit it (even though, yes, they do inhibit alloimmune responses). Ferrara’s goal is to move steroids to 2nd line tx for GVHD!

020

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 07/02/2026

#tandem26 Ferrara: thus far, most GVHD pox/treatment has focused on the intimation and persistence of the alloimmune response, but efforts to improve tissue resistance to damage are important. Eg, intestinal stem cells are damaged by GVHD cytokines. Rux prevents ISC apoptosis, but steroids don’t.

020

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 07/02/2026

#tandem26 Ferrara: refinement of biomarker + clinical sx based aGVHD stratification (MAGIC composite) now gives greater clarity in predicting outcomes at onset of aGVHD.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 07/02/2026

#tandem26 Ferrara: beautiful and touching start to his E Don Thomas lecture by dedicating the talk to John Galvin, who we shockingly lost this past year at far, far too young an age.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 07/02/2026

#tandem26 Unfortunately, I could only make the end of Stella Davies’s Bortin Lecture, but absolute respect to her for using her platform to speak out against the anti-immigrant, anti-democratic trajectory of our current course in America! “We can not sit this one out.” Agree 1000000% !!!

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Rafati: in triple neg MF, TET2mut assoc with incr relapse and inferior OS, whereas TET2mut doesn’t affect outcomes with MF with canonical driver mutation.

010

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Rafati: triple neg MF have inferior alloHCT outcomes. Overall conventional high risk gene must not assoc w survival, but TP53m assoc w inferior outcome with any driver mutation.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Rafati: driver mut found in 81.7%. 18% were triple neg. 94% found to have at least one somatic mut, 1/3 with ASXL1.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Rafati: @cibmtr.bsky.social analysis of genetic predictors of alloHCT outcomes in myelofibrosis. Known high risk assoc w ASXL1+nonCALR/MPL muts. N=930 evaluated here w 95 gene assay.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Popat: age and IPSS not correl w outcomes. TP53 mut status was assoc w 3yr PFS/OS 64% with TP53wt vs 50% with TP53m. Relapse >3x higher in TP53m. Impressive outcomes, but the high NRM is problematic, esp for TP53wt — ie at 12mos, only 6% relapse but OS 69% due to the high toxicity.

020

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Popat: N=50 w HR-MDS underwent CLADILLAC allo. Median age 63, 84% matched donors, 94% PBSC. 28% with TP53 abnormalities. 3yr PFS/OS both 60%, relapse 10%, NRM 30%.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Popat: updated outcomes on CLADILLAC conditioning for MAC allo in HR-MDS. ~1/3 cured with current standard approaches. Age 18-70 eligible for this trial. N=50.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Gyurkocza: low precond BTNL3 expression was associated with poor outcomes in those who recd TBI.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Gyurkocza: several genes associated with outcomes when expressed highly precond, especially CCDC144A. At day 0, CD34 and CACNA1 expression assoc with PFS/OS.

010

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Gyurkocza: FluTreo with TBI N=17 vs 14 wo TBI. Bulk marrow RNAseq used with ML assisted analyses.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Gyurkocza: differential gene expression during conditioning correlate with outcomes in AML/MDS. Marrow collected pre cond and at day 0 after FluTreo +/- TBI200. N=30 evaluable.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Duarte: MDS/MPN N=94 vs MDS N=476. Median older age in MDS/MPN and lower KPS. OS and RFS lower in MDS/MPN, with slightly higher (not significant) NRM.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Duarte: allo outcomes in MDS/MPN syndromes (CMML et al) vs other MDS, a Brazilian analysis. N=570 across 33 centers.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Kongtim: although better survival outcomes with FM regimens, they were associated with higher early TRM.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Kongtim: FM regimens (100/140) outperform other Flu based conditioning wrt DFS/CIR/OS.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Kongtim: @cibmtr.bsky.social analysis of Flu/Mel vs other RIC in pts age 50+ with AML/MDS relapse, total N=11,731 from 183 centers. ~94% PBSC

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Reshef: AlloHeme also outperformed standard bone marrow analyses for MRD, meaning this approach can decrease dependence on marrows since AlloHeme is performed on PB.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Reshef: AlloHeme has good test performance characteristics, including 95% NPV and ROC AUC 0.89. Lead time between AlloHeme+ and clinical relapse was median 41days (not diff between AML and MDS, interestingly). AlloHeme outperforms standard chimerism.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Reshef: AlloHeme evaluable were N=198. At 2, 3, and 6mos post-also AlloHeme positivity highly associated with relapse.

010

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Reshef: AlloHeme, a PB test to predict post-transplant AML/MDS relapse, does not require prior leukemia marker ID. N=285 in ACROBAT study to evaluate this test.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Dvorak: higher exposure to ATG decr GVHD risk but may abrogate GVL and expose to incr infections. Really should incorporate absolute T cell count and timing of administration into ATG dosing to personalize.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Dvorak: ATG effect influenced by number T cells present in the host (and that ratio is not generally manipulated other than TCD).

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Dvorak: increased exposure to TBI, Busulfan, and Melphalan all associated with incr GVHD risk.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Dvorak: conditioning regimen toxicity known to have strong correlation with development of GVHD

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Dvorak: optimal HSPC dose unknown, but infused CD3 dose does not affect GVHD outcomes with a/b TCD, but CD34 dose does influence GVHD risk (surrogate for more APC transfer?).

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Dvorak: maternal effect more pronounced if older. Could it be related to CHIP?

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Dvorak: many variables influence GVHD incidence. In peds haplo, a/b TCD superior to PTCy or CNI but the donor relatedness matter. Worst is mother which is surprising.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Dvorak: a/b TCD assoc with less GVHD and higher GRFS but more graft failure vs unmanipulated graft with PTCy.

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Dvorak: ex vivo TCD (commonly used in peds) vs PTCy in haploHCT

000

Aaron Logan, MD, PhD, MPhil @hemedoc.bsky.social · 06/02/2026

#tandem26 #bmtsm Reddy: classically MHc-I important to activate CD8 responses and protect from NK cell attack, but also plays role in protecting host tissues from CD4 attack.

000